ONCOCYTE CORP (OCX) Stock Fundamental Analysis

NASDAQ:OCX • US68235C2061

3.2 USD
+0.47 (+17.22%)
At close: Jun 17, 2025
3.17 USD
-0.03 (-0.94%)
After Hours: 6/17/2025, 8:05:27 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OCX. OCX was compared to 521 industry peers in the Biotechnology industry. Both the profitability and financial health of OCX have multiple concerns. OCX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year OCX has reported negative net income.
  • OCX had a negative operating cash flow in the past year.
  • OCX had negative earnings in each of the past 5 years.
  • OCX had a negative operating cash flow in each of the past 5 years.
OCX Yearly Net Income VS EBIT VS OCF VS FCFOCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • OCX has a worse Return On Assets (-96.52%) than 75.27% of its industry peers.
  • OCX's Return On Equity of -570.19% is on the low side compared to the rest of the industry. OCX is outperformed by 79.57% of its industry peers.
Industry RankSector Rank
ROA -96.52%
ROE -570.19%
ROIC N/A
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCX Yearly ROA, ROE, ROICOCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 52.56%, OCX is in the better half of the industry, outperforming 77.24% of the companies in the same industry.
  • In the last couple of years the Gross Margin of OCX has declined.
  • OCX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
OCX Yearly Profit, Operating, Gross MarginsOCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • OCX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for OCX has been increased compared to 1 year ago.
  • OCX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for OCX is higher compared to a year ago.
OCX Yearly Shares OutstandingOCX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
OCX Yearly Total Debt VS Total AssetsOCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -7.51, we must say that OCX is in the distress zone and has some risk of bankruptcy.
  • OCX has a Altman-Z score of -7.51. This is in the lower half of the industry: OCX underperforms 69.00% of its industry peers.
  • OCX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.05, OCX is not doing good in the industry: 62.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -7.51
ROIC/WACCN/A
WACC8.92%
OCX Yearly LT Debt VS Equity VS FCFOCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • OCX has a Current Ratio of 3.75. This indicates that OCX is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.75, OCX perfoms like the industry average, outperforming 43.01% of the companies in the same industry.
  • A Quick Ratio of 3.70 indicates that OCX has no problem at all paying its short term obligations.
  • OCX has a Quick ratio of 3.70. This is comparable to the rest of the industry: OCX outperforms 44.27% of its industry peers.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.7
OCX Yearly Current Assets VS Current LiabilitesOCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 31.19% over the past year.
  • OCX shows a strong growth in Revenue. In the last year, the Revenue has grown by 178.48%.
  • OCX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.09% yearly.
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
Revenue 1Y (TTM)178.48%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%

3.2 Future

  • Based on estimates for the next years, OCX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.86% on average per year.
  • OCX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 197.76% yearly.
EPS Next Y78.19%
EPS Next 2Y33.55%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue Next Year508.91%
Revenue Next 2Y196.65%
Revenue Next 3Y197.76%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OCX Yearly Revenue VS EstimatesOCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
OCX Yearly EPS VS EstimatesOCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • OCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCX Price Earnings VS Forward Price EarningsOCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCX Per share dataOCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • OCX's earnings are expected to grow with 21.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.55%
EPS Next 3Y21.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for OCX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ONCOCYTE CORP

NASDAQ:OCX (6/17/2025, 8:05:27 PM)

After market: 3.17 -0.03 (-0.94%)

3.2

+0.47 (+17.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12
Earnings (Next)08-06
Inst Owners56.3%
Inst Owner Change1.79%
Ins Owners0.97%
Ins Owner Change0%
Market Cap91.52M
Revenue(TTM)3.84M
Net Income(TTM)-58.26M
Analysts75
Price Target5.53 (72.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-178.01%
Min EPS beat(2)-347.17%
Max EPS beat(2)-8.85%
EPS beat(4)1
Avg EPS beat(4)-110.58%
Min EPS beat(4)-347.17%
Max EPS beat(4)36.24%
EPS beat(8)3
Avg EPS beat(8)-69.43%
EPS beat(12)6
Avg EPS beat(12)-56.88%
EPS beat(16)8
Avg EPS beat(16)-44.6%
Revenue beat(2)2
Avg Revenue beat(2)1470.69%
Min Revenue beat(2)1371.29%
Max Revenue beat(2)1570.08%
Revenue beat(4)2
Avg Revenue beat(4)707.66%
Min Revenue beat(4)-67.67%
Max Revenue beat(4)1570.08%
Revenue beat(8)4
Avg Revenue beat(8)355.12%
Revenue beat(12)4
Avg Revenue beat(12)213.18%
Revenue beat(16)5
Avg Revenue beat(16)144.09%
PT rev (1m)20.37%
PT rev (3m)31.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.05%
EPS NY rev (1m)-3.26%
EPS NY rev (3m)38.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)106.51%
Revenue NY rev (3m)195.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.81
P/FCF N/A
P/OCF N/A
P/B 8.96
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.13
BVpS0.36
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -96.52%
ROE -570.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.56%
FCFM N/A
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.45%
Cap/Sales 20.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.75
Quick Ratio 3.7
Altman-Z -7.51
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)44.29%
Cap/Depr(5y)100.36%
Cap/Sales(3y)166.07%
Cap/Sales(5y)140.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
EPS Next Y78.19%
EPS Next 2Y33.55%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue 1Y (TTM)178.48%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%
Revenue Next Year508.91%
Revenue Next 2Y196.65%
Revenue Next 3Y197.76%
Revenue Next 5YN/A
EBIT growth 1Y55.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.32%
EBIT Next 3Y10.61%
EBIT Next 5YN/A
FCF growth 1Y47.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.8%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOCYTE CORP / OCX FAQ

Can you provide the ChartMill fundamental rating for ONCOCYTE CORP?

ChartMill assigns a fundamental rating of 2 / 10 to OCX.


What is the valuation status for OCX stock?

ChartMill assigns a valuation rating of 1 / 10 to ONCOCYTE CORP (OCX). This can be considered as Overvalued.


Can you provide the profitability details for ONCOCYTE CORP?

ONCOCYTE CORP (OCX) has a profitability rating of 1 / 10.